GSK (LSE:GSK) has been on investor radars after recent trading performance, with the share price showing a 1.1% decline over ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value ...

The FTSE 100 Index continued its rally this week and was hovering near its all-time high as market participants reacted to ...

Investors with a lot of money to spend have taken a bearish stance on GSK (NYSE:GSK). And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's ...

The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.

The acquisition was announced on Tuesday, News.Az reports, citing Reuters. This marks GSK's first major purchase under the ...